Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Cash from Investing Activities (2020 - 2024)

Gain Therapeutics has reported Cash from Investing Activities over the past 5 years, most recently at -$43447.0 for Q4 2024.

  • Quarterly results put Cash from Investing Activities at -$43447.0 for Q4 2024, down 101.38% from a year ago — trailing twelve months through Dec 2024 was $5.0 million (down 51.31% YoY), and the annual figure for FY2024 was $5.0 million, down 51.31%.
  • Cash from Investing Activities for Q4 2024 was -$43447.0 at Gain Therapeutics, down from -$1.0 in the prior quarter.
  • Over the last five years, Cash from Investing Activities for GANX hit a ceiling of $3.1 million in Q4 2023 and a floor of -$14.9 million in Q2 2022.
  • Median Cash from Investing Activities over the past 5 years was -$3156.5 (2020), compared with a mean of $15516.2.
  • Biggest five-year swings in Cash from Investing Activities: plummeted 66066.32% in 2022 and later soared 27026.26% in 2023.
  • Gain Therapeutics' Cash from Investing Activities stood at -$14551.0 in 2020, then grew by 23.73% to -$11098.0 in 2021, then surged by 1305.89% to $133830.0 in 2022, then surged by 2247.65% to $3.1 million in 2023, then plummeted by 101.38% to -$43447.0 in 2024.
  • The last three reported values for Cash from Investing Activities were -$43447.0 (Q4 2024), -$1.0 (Q3 2024), and $2.0 million (Q2 2024) per Business Quant data.